Update on a Promising New Drug to Treat JM: Vamorolone

Cure JM is making extraordinary progress in juvenile myositis (JM) research, including a partnership with ReveraGen Biotech to advance the drug vamorolone toward a clinical trial in JM.

Vamorolone is a steroid replacement. It has all of the benefits of steroid treatment without the devastating side effects. Vamorolone is currently in a clinical trial in Duchenne Muscular Dystrophy children.

Findings so far indicate improved safety relative to prednisone. Cure JM is working with vamorolone’s sponsor, ReveraGen, to design a clinical trial to test the safety of the drug in JM children. ReveraGen’s VP of Research, Eric Hoffmann, PhD, gives us an update on vamorolone and the status of a clinical trial in JM.

What is Juvenile Myositis?

Juvenile myositis, including juvenile dermatomyositis and juvenile polymyositis, is a group of rare and life-threatening autoimmune diseases, in which the body’s immune system attacks its own cells and tissues.

Treatment Plans for Juvenile Myositis

A treatment plan is based on many factors, including the severity and expression of the juvenile dermatomyositis (JDM). Each case is different and the symptoms can change over time.

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.